
IN THE CLAIMS

Please amend the claims as follows:



9.

(Previously Presented)

polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

The composition of

Claim

7,

wherein

the

- 10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.
- 11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Canceled)

13. (Currently Amended) The composition of Claim 1 wherein the <u>e-PTFE</u> biocompatible micronized textured polyethylene and the <u>PVP</u> carrier are combined at a ratio of approximately 3:2 polyvinylpyrrolidone carrier to <u>e-PTFE</u> biocompatible micronized textured polyethylene by weight.

14. (Canceled)

- 15. (Withdrawn) A method for tissue augmentation comprising:

 injecting a biphasic injectable composition comprising:

 solid polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.
- 16. (Withdrawn) The method of Claim 15, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

3

- 17. (Withdrawn) The method of Claim 15, wherein the liquid carrier substrate is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.
- 18. (Withdrawn) The method of Claim 15, wherein injecting comprises:

 inserting a delivery apparatus containing the biphasic injectable composition into the injection site.
- 19. (Withdrawn) The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.
- 20. (New) The composition of Claim 1, wherein the textured particles have a size greater than eighty microns.
- 21. (New) The composition of Claim 1, wherein the textured particles have a size greater than one-hundred microns.
 - 22. (New) A biphasic injectable composition comprising:

biocompatible micronized textured polyethylene particles having a size of greater than sixty microns; and

a carrier comprising polyvinylpyrrolidone.

- 23. (New) The composition of Claim 22 wherein the biocompatible micronized textured polyethylene and the carrier are combined at a ratio of approximately 3:2 carrier to biocompatible micronized textured polyethylene by weight.
- 24. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

- 25. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.
- 26. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.
- 27. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.
- 28. (New) The composition of Claim 22, wherein the textured particles have a size greater than eighty microns.
- 29. (New) The composition of Claim 22, wherein the textured particles have a size greater than one-hundred microns.

1231077_2.DOC